Skip to main content

新しいFDAガイダンスのプロジェクト・オプティマスが、オンコロジー臨床試験、医薬品パイプラインの今後に及ぼす可能性のある影響について

Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.

Powered by Translations.com GlobalLink OneLink Software